Incyte

INCY

Market cap $19.3B

Incyte's Monjuvi as part of a multi-drug regimen that includes a chemotherapy standard of care ‌for an aggressive form of non-Hodgkin lymphoma reduced the risk of disease progression, relapse or death by 25% compared to the standard alone, but with a higher rate of study dropouts due to side effects.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's frontMIND trial found Tafasitamab (Monjuvi/Minjuvi) combo significantly prolongs progression-free survival in high-risk DLBCL patients.

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference.

Incyte NASDAQ: INCY Chief Medical Officer Steven Stein outlined the company's development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody 989, during a company news event.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

In this week's edition of InnovationRx, we look at a new AI drug development deal, a pill for sleep apnea, Commure's $7 billion valuation, and more. To get it in your inbox, subscribe here.

WILMINGTON, Del. & SAN MATEO, Calif.--(BUSINESS WIRE)--Incyte and Genesis expand molecular AI collaboration to accelerate 
drug discovery.